Health · Healthcare & Policy · 2 days ago
India approves 30% trade-margin cap on non-scheduled cancer drugs
India’s National Pharmaceutical Pricing Authority has approved a cap on trade margins for non-scheduled cancer medicines.
The margin is the amount added to a medicine’s price as it moves through the supply chain.
Under the proposal, it cannot exceed 30% of the maximum retail price for medicines on a list that has yet to be finalised.
The measure is intended to cover branded and generic medicines, including imported and domestically made products.
The authority found that average mark-ups were around 170%, with some reaching 700%, and that prices varied across pharmacies.
Cancer treatment costs are a major burden for patients, with about 75% of treatment spending estimated to be paid out of pocket.
The government expects the cap to lower medicine prices by 20% to 70% and save patients about ₹2,500 crore a year.
Manufacturers will be required to maintain existing production levels, and an expert committee will finalise which medicines are covered.
India’s National Pharmaceutical Pricing Authority has approved a 30% cap on trade margins for identified non-scheduled cancer drugs.
The cap is based on the drugs’ maximum retail price, and the list of medicines covered is still to be finalised.
The government expects prices to fall by up to 70% and patients to save about ₹2,500 crore a year.
The measure is intended to reduce patients’ out-of-pocket costs and excessive mark-ups across the distribution chain.
- Who
- India’s National Pharmaceutical Pricing Authority (NPPA) approved the proposal.
- What
- Trade margins on identified non-scheduled anti-cancer drugs will be capped at 30% of the maximum retail price. The medicines to be covered are yet to be finalised.
- When
- The decision was reported on October 8 and 9, 2026.
- Where
- India.
- Why
- To make cancer treatment more affordable and reduce patients’ out-of-pocket expenditure.
This story does not have two clearly opposing sides.
The Authority unanimously agreed that, in view of excessive profiteering in anti-cancer drugs and its impact on patients, consumer interest must remain paramount.
To ensure availability, manufacturers will be required to maintain their existing production level.
The NPPA capped trade margins on selected non-scheduled anti-cancer drugs, with reported price reductions of up to 91%.
The Hindu reported that the government had decided to cap trade margins at 30% of MRP for non-scheduled anti-cancer drugs.
News18 reported that the NPPA had approved the proposal in principle, pending finalisation of the covered drug list.
- Trade margin cap
- 30% of maximum retail price
- Expected price reduction
- Up to 70%
- Estimated annual patient savings
- Approximately ₹2,500 crore
- Cancer medicine market turnover
- Approximately ₹12,500 crore a year
- Non-scheduled anti-cancer drug mark-ups
- Average around 170%; up to 700% in some cases
Sources
Related news
Demand grows for death doulas who support people near the end of life
Elder care managers help US families navigate care and paperwork
Brain stimulation centre opens at medical institute in Guntur
KPN outage disrupts phone access to several Dutch university hospitals
Humana gains in 2027 Medicare Advantage ratings as Alignment falls
Hospitals sue to block revised federal 340B drug rebate plan
India proposes approval requirement for prescription drug ads by sellers
Medicine shortages reported at camps near Vijayawada’s Kanaka Durga temple
Moving a loved one into a care home can be hard on family caregivers
Luigi Carbone coordinates medical care for Pope Leo XIV
Medicaid cuts raise risk of more US maternity ward closures
